When cancer drugs do their job, the cells in a patient’s tumor will ultimately slow their rate of mass accumulation and die. However, this can be difficult to measure until treatment is underway, and in many cases, the cells’ susceptibility to treatment is invariability overridden at some point by a phenomenon known as acquired resistance. The KI’s Manalis lab, in partnership with clinicians and other researchers working under the auspices of the KI-DF/HCC Bridge Project, has mobilized their suspended microchannel resonators to quickly and accurately determine drug sensitivity (and resistance) by analyzing how mass accumulation of individual cancer cells changes after exposure to different drugs. The researchers are currently determining if their approach can successfully predict patient response for personalized medicine, and also hope to use their findings to better understand the mechanisms by which resistance develops.